The experimental studies of AYUSH 64 has shown that it was safe and non-toxic in the dose of 500 mg/kg of body weight for 12 weeks. It is found to be effective in fevers of unknown etiology, filarial lymphangitis and derangement of liver function besides its anti-malarial activity.Taking leads from the clinical experiences of physicians who had successfully used AYUSH 64, for management of Influenza like Illness (ILI), a pilot study was conducted by  CCRAS, which concluded recently and is under the process of publication. This study was done in 34 cases of flu like illness, wherein Ayush 64 helped to recover from ILI symptoms with reduced frequency of usage of acetaminophen and antihistaminic. This lead to the idea of repurposing AYUSH 64 for use in the management of COVID positive cases. So a single arm, open, prospective, non-controlled, interventional pilot study was conducted at Chaudhary Brham Prakash Ayurved Charak Sanstha (CBPACS), Khera Dabar, Najafgarh. A total of 64 patients of either sex above 18 years of age, confirmed cases of COVID 19 disease have been screened for taking 40 patient and 37 patients were enrolled in the study. The enrolled patients were assessed at baseline, 8th day and 15th day after their enrolment in the study. Out of 37 patients, 4 were drop out and rest 33 completed the study. Out of the completed 33 patients, 18 patients became COVID negative on 8^th day and 7 patients became COVID negative on 15^th day. 8 patients were those, who were COVID positive after completion of the trial.